Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00904826

An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica

Sponsor: Alexion Pharmaceuticals, Inc.

Conditions Devic's Disease Neuromyelitis Optica

Interventions Eculizumab

Updated 10 times since 2017 Last updated: Aug 30, 2013 Started: Apr 30, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00904826, this PHASE1/PHASE2 trial focuses on Devic's Disease and Neuromyelitis Optica and remains completed. Sponsored by Alexion Pharmaceuticals, Inc., it has been updated 10 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Dec 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Apr 2023 — Dec 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2023 — Apr 2023 [monthly]

Completed PHASE1_PHASE2

▶ Show 5 earlier versions

Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Apr 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alexion Pharmaceuticals, Inc.
Mayo Clinic

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States
• Scottsdale, United States